There are currently 632 clinical trials in Louisville, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Louisville, Jewish Hospital, Norton Cancer Institute and Saints Mary and Elizabeth Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
NCT05856760
Recruiting
This is a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Travere Investigational Site, Louisville, Kentucky
Conditions: Immunoglobulin A Nephropathy
Register for Updates
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624
Recruiting
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Norton Cancer Center, Louisville, Kentucky
Conditions: Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200
Recruiting
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/18/2024
Locations: GSK Investigational Site, Louisville, Kentucky
Conditions: Colonic Neoplasms, Neoplasms, Colon
Register for Updates
Alcoholic Hepatitis Network Observational Study
NCT03850899
Recruiting
The purpose of this research study is to create a clinical database and bio-repository. To do this, we will obtain blood, urine, saliva, and stool samples (e.g., biological samples) and personal health information from you to use in future research studies related to alcoholic hepatitis or other diseases. Part of your blood sample will be used to extract your DNA. DNA is the genetic material that gives us unique characteristics. We are doing this research study because we are trying to find out... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
02/16/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Alcoholic Hepatitis
Register for Updates
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
NCT05175352
Recruiting
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/15/2024
Locations: University Of Louisville, Louisville, Kentucky
Conditions: Eosinophilic Esophagitis
Register for Updates
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma
NCT05561374
Recruiting
This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Norton Healthcare, Louisville, Kentucky
Conditions: High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Norton Heart Specialists, Louisville, Kentucky
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
Prospective Case Collection Study for New Mammography Technologies
NCT05199701
Recruiting
To evaluate the safety and efficacy of the proposed investigational device and assess its clinical utility in breast cancer screening and diagnosis to support continuing technology development of the investigational technology.
Gender:
Female
Ages:
Between 35 years and 100 years
Trial Updated:
02/14/2024
Locations: Baptist Health, Louisville, Kentucky
Conditions: Mammography
Register for Updates
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
NCT04329728
Recruiting
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Gender:
All
Ages:
Between 12 years and 95 years
Trial Updated:
02/13/2024
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Lymphoid Malignancies
Register for Updates
Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients
NCT04756076
Recruiting
Investigators plan to recruit 50 PAH patients from UofL PAH Clinic, with various degrees of severity (25 intermediate risk patients and 20 high risk patients) and 10 age and gender matched controls. PAH patients are evaluated at least every 6 months by the PAH Clinic and blood/urine samples will be obtained at each office visit. Blood, plasma and urine samples will be used to measure 31 metal levels including heavy metals (cadmium, arsenic, cobalt, lead etc.) and essential metals (calcium, coppe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: University of Louisville Health, Louisville, Kentucky
Conditions: Pulmonary Hypertension, Metal Poison
Register for Updates
Pembrolizumab Plus Olaparib in LA-HNSCC
NCT05366166
Recruiting
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck squamous cell carcinoma. Pembrolizumab and olaparib are drugs that are approved for head and neck cancer treatment. However, FDA has not approved the use of these two drugs together in treating head and neck cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: University of Louisville, Brown Cancer Center, Louisville, Kentucky
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates